Burzynski Research Institute (BZYR) Operating Expenses (2010 - 2025)
Burzynski Research Institute (BZYR) posted Operating Expenses of $328862.0 for Q4 2025, down 1.5% sequentially from $333867.0 in Q3 2025, and down 6.64% YoY from $352239.0 in Q4 2024.
Burzynski Research Institute (BZYR) Operating Expenses (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Operating Expenses for 16 years, with the latest figure at $328862.0 in Q4 2025.
- Quarterly Operating Expenses fell 6.64% year-over-year to $328862.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $1.3 million (down 11.63% YoY) and the FY2025 annual result came in at $1.4 million, up 3.8% from the prior year.
- Operating Expenses eased to $328862.0 in Q4 2025 per BZYR's latest filing, from $333867.0 in the prior quarter.
- Over five years, Operating Expenses peaked at $433015.0 in Q4 2023 and troughed at $170879.0 in Q1 2022.
- A 5-year average of $292985.1 and a median of $290101.5 in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses slumped 31.9% in 2022, then soared 71.4% in 2023.
- Over 5 years, Operating Expenses stood at $264776.0 in 2021, then retreated by 4.58% to $252639.0 in 2022, then soared by 71.4% to $433015.0 in 2023, then fell by 18.65% to $352239.0 in 2024, then retreated by 6.64% to $328862.0 in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $328862.0, $333867.0, and $331451.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 328,862.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 328,862.00 |
| Aug 31, 2025 | 333,867.00 |
| May 31, 2025 | 331,451.00 |
| Feb 28, 2025 | 292,798.00 |
| Nov 30, 2024 | 352,239.00 |
| Aug 31, 2024 | 369,838.00 |
| May 31, 2024 | 371,332.00 |
| Feb 29, 2024 | 362,907.00 |
| Nov 30, 2023 | 433,015.00 |
| Aug 31, 2023 | 252,104.00 |
| May 31, 2023 | 287,405.00 |
| Feb 28, 2023 | 215,998.00 |
| Nov 30, 2022 | 252,639.00 |
| Aug 31, 2022 | 215,918.00 |
| May 31, 2022 | 231,737.00 |
| Feb 28, 2022 | 170,879.00 |
| Nov 30, 2021 | 264,776.00 |
| Aug 31, 2021 | 224,718.00 |
| May 31, 2021 | 316,283.00 |
| Feb 28, 2021 | 250,936.00 |